Bradley McGregor, MD
, clinical director at Lank Center for Genitourinary Oncology, senior physician at Dana-Farber Cancer Institute
, and instructor of medicine at Harvard Medical School, discusses a new clinical trial for patients with non-clear cell renal cell carcinoma (RCC) using a combination of atezolizumab and bevacizumab to target PD-L1 and VEGF. Since most recent clinical trials focus on clear cell RCC, Dr. McGregor emphasizes the importance of this clinical trial, which had a 33% overall response rate for a cohort of 42 patients with non-clear cell RCC with variant histology and 18 patients with clear cell RCC with sarcomatoid differentiation, due to the associated poor prognosis.
Learn more by clicking here